Title:
上皮成長因子受容体キナーゼ阻害剤に対する抗癌応答を予測する生物学的マーカー
Document Type and Number:
Japanese Patent JP5085529
Kind Code:
B2
Abstract:
The present invention provides diagnostic and prognostic methods for predicting the effectiveness of treatment of a cancer patient with an EGFR kinase inhibitor. Methods are provided for predicting the sensitivity of tumor cell growth to inhibition by an EGFR kinase inhibitor, comprising assessing whether the tumor cell has undergone an epithelial to mesenchymal transition (EMT), by determining the expression level of epithelial and/or mesenchymal biomarkers, wherein tumor cells that have undergone an EMT are substantially less sensitive to inhibition by EGFR kinase inhibitors. Improved methods for treating cancer patients with EGFR kinase inhibitors that incorporate the above methodology are also provided. Additionally, methods are provided for the identification of new biomarkers that are predictive of responsiveness of tumors to EGFR kinase inhibitors. Furthermore, methods for the identification of agents that restore the sensitivity of tumor cells that have undergone EMT to inhibition by EGFR kinase inhibitors are also provided.
More Like This:
Inventors:
Hailey, Jiyoung Day
Griffin, Graham
Lucer Tse Amler
Everhard, David A
Robert Elle, York
Griffin, Graham
Lucer Tse Amler
Everhard, David A
Robert Elle, York
Application Number:
JP2008502016A
Publication Date:
November 28, 2012
Filing Date:
March 16, 2006
Export Citation:
Assignee:
OSI Pharmacy Youticals LLC
Genentech, Incorporated
Genentech, Incorporated
International Classes:
G01N33/50; A61K45/00; A61P35/00; A61P43/00; G01N33/15; G01N33/574
Domestic Patent References:
| JP2004275145A | ||||
| JP2000511433A |
Foreign References:
| WO2003101491A1 | ||||
| WO2004046386A1 |
Other References:
MATAR PABLO,CLINICAL CANCER RESEARCH,2004年10月 1日,V10 N19,P6487-6501
WITTA SE,PROC AMER ASSOC CANCER RES [ONLINE],2004年,V45,URL,http://www.aacrmeetingabstracts.org/cgi/content/abstract/2004/1/847
KAMALATI T,THE JOURNAL OF BIOLOGICAL CHEMISTRY,1996年11月29日,V271 N48,P30956-30963
KANG YIBIN,CELL,2004年 8月 6日,V118 N3,P277-279
SAKURAI H,PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA,米国,NATIONAL ACADEMY OF SCIENCE,1997年 6月,V94,P6279-6284
CHUNG LELAND W K,THE JOURNAL OF UROLOGY,2005年 1月,V173 N1,P10-20
WITTA SE,PROC AMER ASSOC CANCER RES [ONLINE],2004年,V45,URL,http://www.aacrmeetingabstracts.org/cgi/content/abstract/2004/1/847
KAMALATI T,THE JOURNAL OF BIOLOGICAL CHEMISTRY,1996年11月29日,V271 N48,P30956-30963
KANG YIBIN,CELL,2004年 8月 6日,V118 N3,P277-279
SAKURAI H,PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA,米国,NATIONAL ACADEMY OF SCIENCE,1997年 6月,V94,P6279-6284
CHUNG LELAND W K,THE JOURNAL OF UROLOGY,2005年 1月,V173 N1,P10-20
Attorney, Agent or Firm:
Kayo Shiina
Yoshio Kawaguchi
Makoto Ono
Chihiro Watanabe
Kenkyo Kanayama
Katsuma Osaki
Mitsuaki Tsubokura
Yoshio Kawaguchi
Makoto Ono
Chihiro Watanabe
Kenkyo Kanayama
Katsuma Osaki
Mitsuaki Tsubokura